These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 145518

  • 41. Pott's disease following BCG therapy of melanoma.
    Strausser JL, Quindlen EA.
    Cancer; 1981 Sep 01; 48(5):1154-6. PubMed ID: 7272949
    [Abstract] [Full Text] [Related]

  • 42. Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.
    Briggs PC, Heckler FR.
    Plast Reconstr Surg; 1988 Jun 01; 81(6):952-3. PubMed ID: 3375359
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP, Douglass HO, Yeracaris PM, Holyoke ED.
    Arch Surg; 1976 Jun 01; 111(6):716-8. PubMed ID: 776125
    [Abstract] [Full Text] [Related]

  • 47. Treatment of malignant melanoma by intratumoral injection of BCG.
    Pinsky CM, Hirshaut Y, Oettgen HF.
    Natl Cancer Inst Monogr; 1973 Dec 01; 39():225-8. PubMed ID: 4595322
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Hypersensitivity as an immunological phenomena].
    Kosunen T.
    Duodecim; 1968 Dec 01; 84(2):109-15. PubMed ID: 4232965
    [No Abstract] [Full Text] [Related]

  • 50. Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma.
    Millar JW, Hunter AM, Wightman AJ, Horne NW.
    Eur J Respir Dis; 1980 Jun 01; 61(3):162-6. PubMed ID: 7439279
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Jun 01; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 53. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
    Pinsky CM, Hirshaut Y, Wanebo HJ, Fortner JG, Miké V, Schottenfeld D, Oettgen HF.
    Ann N Y Acad Sci; 1976 Jun 01; 277(00):187-94. PubMed ID: 1069548
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
    Buckley CE, White DH, Seigler HF.
    Monogr Allergy; 1977 Jun 01; 11():97-105. PubMed ID: 876133
    [Abstract] [Full Text] [Related]

  • 57. [Development in the immunotherapy of malignant melanoma].
    Tritsch H.
    Hautarzt; 1976 Jan 01; 27(1):1-7. PubMed ID: 767300
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. The immunotherapy of acute myelogenous leukaemia using intravenous BCG.
    Whittaker JA, Slater AJ.
    Br J Haematol; 1977 Feb 01; 35(2):263-73. PubMed ID: 322696
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.